2A Biosciences Inc. has divulged compounds acting as 5-HT2A and 5-HT2C receptor agonists reported to be useful for the treatment of atopic dermatitis, conjunctivitis, Crohn’s disease, type 2 diabetes, ...

Signals in our brain are not always processed in the same way: Certain receptors modulate these mechanisms, influencing our mood, perception, and behavior in various ways. One of these is the 5-HT2A ...

Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

Understanding exactly how psychedelics promote new connections in the brain is critical to developing targeted, non-hallucinogenic therapeutics that can treat neurodegenerative and neuropsychiatric ...

Gilgamesh Pharmaceuticals’ psychedelic therapy has boasted a 94% depression remission rate after 29 days in a Phase IIa study. The trial (NCT06236880) investigated the efficacy, safety and durability ...

SEATTLE--(BUSINESS WIRE)--Küleon LLC, a preclinical-stage biotechnology company building a best-in-class library of selective, G-protein-biased serotonergic medicines, today announced it has been ...